Elutia closes sale of its BioEnvelope business to Boston Scientific for $88M

Elutia (ELUT) announced the closing of the sale of its BioEnvelope business, including the EluPro and CanGaroo bioenvelopes, to Boston Scientific Corporation (BSX) for $88M in cash. With this closing, Elutia will leverage its drug-eluting biologics platform with a more concentrated focus on advancing NXT-41x. “With our significantly strengthened financial position, we plan to bring NXT-41x to market in the first half of 2027,” said Dr. Randy Mills, CEO of Elutia. “We are confident we have the people, technology, and resources to reshape the breast reconstruction treatment paradigm and accelerate our path to positive cash flow. I want to thank the entire Elutia CRU for their relentless work to enable patients everywhere to thrive without compromise.”